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ABSTRACT 
 
This work aimed to determine whether seropositivity to Helicobacter pylori infection was an independent risk factor 
for hyperhomocysteinemia patients with cardiovascular disease. The H. pylori IgG, IgA and homocystein levels in 
96 patients with cardiovascular disease and 64 participants free of cardiovascular disease as control subjects were 
determined by ELISA assay. The results showed that seropositivity to H. pylori IgG and IgA levels of coronary 
artery disease (CAD)patients was significantly higher than the controls and CAD patients with H. pylori IgG and 
IgA negative antibodies. A significant correlation was found between the seropositivity to H. pylori IgG and 
homocysteine levels of CAD patients in comparison with the controls and CAD patients with seronegativity to H. 
pylori IgG and  IgA  (r=0.233, P= 0.019 ). The involvement of H. pylori infection in atherosclerosis process was 
based on the chronic inflammation, which might facilitate the CAD-related pathologies. The effect of the presence of 
H. pylori infection on homocysteine levels elevation in the CAD patients (as a risk factor independent of other 
traditional factors) was remarkable. 
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INTRODUCTION 
 
Cardiovascular disease is the most common cause 
of mortality and morbidity in the United States and 
many other nations (Reddy-Vanga et al. 2010). 
Coronary atherosclerosis process is multi-factorial. 
Traditional and classic cardiovascular risk factors 
such as diabetes mellitus (DM), hypertension 
(HTN), smoking and obesity have introduced as 
major causes, but significant proportions of the 
patients with coronary artery disease (CAD) do not 
have these traditional risks. Other factors, which 
may affect this chronic process, have been 
evaluated (Folsom et al. 1998; Reddy-Vanga et al. 
2010; Rogha et al. 2012). For example, infection-
related chronic inflammation from Helicobacter 
pylori (H. pylori) is one of the CAD risk factors, 
because the CAD risk factors plasma fibrinogen, 
C-reactive protein, and blood leukocyte count 
become elevated in the seropositive subjects 
(Folsom et al. 1998). H. pylori infection is the 
most common infection worldwide, especially in 
the developing countries (Rogha et al. 2012). 
According to many reports, 70-90% of apparently 
healthy people of developing countries are 
estimated to be infected with H. pylori (Rogha et 
al. 2012; Chmiela et al. 2015; Javadi et al. 2015). 
H. pylori is a Gram-negative bacterium with 
perfect adaptation to the acidic environment of the 
stomach and high affinity to gastric epithelial 
cells.  Recently, possible association between H. 
pylori infection and extragastric disorders has been 
also suggested (Franceschi et al. 2006; Pacifico et 
al. 2010; Pacifico et al. 2014).  An indirect 
association between the prevalence of H. pylori 
and the occurrence of CAD is demonstrated by 
many research studies (Rogha et al. 2012; Chmiela 
et al. 2015; Javadi et al. 2015). A significant 
association of H. pylori infection with CAD (OR 
3.18, 95% CI 1.08-9.40) was shown by a 
multivariate logistic regression analysis (Rogha et 
al. 2012). According to majority of findings, the 
involvement of H. pylori in this process was based 
on the chronic inflammation, which might 
facilitate the CAD-related pathologies (Rogha et 
al. 2012; Chmiela et al. 2015). Several 
mechanisms have been proposed for how H. pylori 
might accelerate macrovascular complications and 
increase CAD risk (Cenerelli et al. 2002; Rogha et 
al. 2012; Javadi et al. 2015).  It has been 
demonstrated that H. pylori is an important and 
serious cause of elevated levels of homocysteine 
(HCY) and is prevalent in the Caucasian 
population, ranging from 30 to 40% incidence. On 
the other hand, HCY is recognized as an 
independent risk factor for cardiovascular 
diseases. HCY has been demonstrated to be toxic 
to the endothelial cells and lipoproteins due to 
generation of oxygen radicals. High level of HCY 
appears to be one of the factors responsible for the 
increased risk of vascular damage and clinical 
CAD events (Sacco et al. 2004). A study on 116 
patients with CAD who were matched with 116 
controls via age and sex although showed a minor 
association between H. pylori infection and CAD. 
However, a stronger correlation between higher 
levels of triglycerides (fats) and lower levels of 
high density high-density lipoprotein (HDL) -
cholesterol was found in the H. pylori-infected 
patients (Laurila et al. 1999; Ekesbo et al. 2000; 
Hoffmeister et al. 2001; Kowalski 2001). Based on 
the above findings, these results could be 
consistent with the hypothesis that H. pylori 
infection might modify the serum lipid 
concentrations in a way that could increase the risk 
of CAD (Sacco et al. 2004). Hence, knowing the 
inflammation as a cardiovascular risk factor in the 
one hand and H. pylori and hyper-
homocysteinemia involvement in CAD incidence 
on the other hand could be interesting to evaluate 
the H. pylori infection effect on HCY levels and 
atherosclerosis processes.  
Thus, this study examined whether H. pylori 
seropositivity was associated with 
hyperhomocysteinemia and cardiovascular disease 
occurrence.  
 
MATERIAL AND METHODS  
 
Sampling and Coronary Angiography 
This study was approved by the Ethical Committee 
of Iran University of Medical Sciences. The cross-
sectional study was performed in Rasool Akram 
Hospital of Tehran from June 2014 to October 
2014. Ninety six consecutive CAD patients (68 
men and 28 women; mean age 52. 95 ±  1.25 and 
51.32 ± 1.61 years old, respectively) and 64 
controls were enrolled into the study and 
candidates for coronary angiography and informed 
consent were selected. Before catheterization, all 
the subjects completed a semi-structured 
questionnaire regarding their past medical and 
drug history. The diagnosis was based on the 
decision of an experienced clinician. Coronary 
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angiography was carried out by left-heart 
catheterization and arteriography using Judkins 
method, and then a cardiologist separately 
reviewed the angiography films. According to 
angiography reports, the clinical and laboratory 
evaluated patients with ≥50% coronary stenosis 
were considered as CAD positive group and 
participants with <50% coronary stenosis were 
considered as CAD negative group, or controls. 
Accordingly, patients with hepatic dysfunction, 
autoimmune disease, thyroid dysfunction and/or 
adrenal dysfunction as well as patients who 
consumed any kinds of glucocorticoids were 
excluded from the study.  
 
Biochemical Measurements  
Fasting blood sample of catheterization 
participants were taken to measure lipid profiles,   
immunoglobulins G and A (anti H. pylori IgG and 
IgA) and homocysteine levels.  ELISA kit 
(Diagnostic kit, PISHTAZ TEB Company, 
Teheran, Iran) was used to measure the 
homocysteine levels. Anti-H. pylori antibody 
status was determined by measuring the IgG and 
IgA antibody by ELISA assay (Diagnostic kit, 
PISHTAZ TEB Company). Spectrophotometric 
assay was used for lipid profiles assay. 
 
Statistical Data Analysis  
Statistical analyses were carried out using SPSS 
software (version 16.0, Chicago, IL, USA). 
Unpaired student t-tests and ANOVA test were 
used for comparing the continuous variable. Chi-
square test was used for discrete variables. To 
compare the association of H. pylori infection with 
homocysteine and thereby CAD, logistic 
regression tests were used by adjusting the sex and 
age plus history of diabetes, dyslipidemia, and/or 
hypertension. 
 
RESULTS 
 
Demographic characteristics of four study groups 
are shown in Tables 1 and 2.  No significant 
differences were found in terms of demographic 
characteristics between the CAD patients and 
controls with anti-H. pylori IgG positive and 
negative and between the CAD patients and 
controls with anti-H. pylori IgA positive and 
negative. As  shown in Table 1, the anti-H. pylori 
IgG  (72.49 ± 3.64U/mL) and IgA  (46.72 ± 3.24 
U/mL) levels of  CAD patient with positive anti -
H. pylori IgG were  significantly more than those 
were found  in the CAD patients with  negative 
anti-H. pylori IgG (9.34 ± 2.11  and  12.20 ± 1.15 
U/mL). The values of 8.05 ± 0.40 and 15.48 ± 3.18 
U/mL were achieved for anti-H. pylori IgG and 
anti-H. pylori IgA of controls with  negative anti-
H.P. IgG, respectively, which were lower  
significantly than those found for CAD patient 
with positive and negative anti-H. pylori IgG. The  
anti-H. pylori IgG  (67.21 ± 4.00 U/mL) and anti-
H. pylori IgA  (38.90  ± 3.68 U/mL) levels of  the 
control group with  positive anti-H. pylori IgG 
were lower than CAD patient with positive anti-H. 
pylori IgG but significantly  higher than negative 
anti-H. pylori IgG CAD patients.  
 
Table 1 - Demographic characteristics of CAD patients and controls with positive and negative 
 anti- H. pylori IgG  
 Control- 
Negative anti-
H.P IgG)
 
N=21 
Control- 
positive 
anti-H.P 
IgG) 
N=43 
CAD-
Negative 
anti-H.P IgG 
N=17  
CAD -
Positive 
anti-H.P IgG 
N=79 
P value 
Gender Male 13 19 9 59 0.008 
Female 8 24 8 20 
Smoking Yes 6 7 6 24 0.309 
No 15 36 11 55 
Diabetes History 
 
Drinking status                       
 
History of hypertension           
Yes 1 4 4 9 0.306 
 
0.307 
 
0.305 
No 
Yes 
No 
Yes 
No 
20 
5 
16 
3 
18 
39 
4 
39 
6 
37 
13 
5 
12 
6 
11 
70 
20                                                    
59 
12 
67 
 
Medication Aspirin Yes 14 34 15 69 0.129 
No 7 9 2 10 
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Statin Yes 8 18 13 59 <0.001 
No 13 25 4 20 
Lozartan Yes 5 7 5 21 0.577 
No 16 36 12 58 
 
Anti H.P IgG( U/mL) 8.05 ± 0.40 67.21 ± 4.00 9.34 ± 2.11 72.49 ± 3.64 <0.001 
Anti H.P IgA (U/mL) 15.48 ± 3.18 38.90 ± 3.68 12.20 ± 1.15 46.72 ± 3.24 <0.001 
LDL-C ( mg/dL) 105.16 ± 6.84 93.97 ± 3.87 99.27 ± 5.41 98.37 ± 3.08 0.507 
HDL-C( mg/dL) 39.53 ± 2.60 38.06 ± 2.06 35.07 ± 1.64 36.96 ± 0.93 0.550 
Cholesterol ( mg/dL) 189.26 ± 11.28 167.58 ± 6.37 168.80 ± 7.85 169.12 ± 4.27 0.199 
TG ( mg/dL) 152.89 ± 22.46 142.25 ±16.29 174.07 ± 23.64 126.53 ± 7.19 0.154 
FBS( mg/dL) 102.40± 4.96 103.21± 6.84 106.26± 6.60 104. 08± 2.53 0.983 
 Age(years) 57.76 ± 2.36 55.49 ± 1.65 56.35 ± 2.47 59.79 ± 1.23 0.187 
SBP(mmHg) 126.55 ± 2.61 131.79 ± 2.98 132.40 ± 1.82 131.04 ± 15.70 0.652 
DBP(mmHg) 78.35 ± 2.19 80.02 ± 1.91 81.27 ± 2.48 83.15 ± 1.56 0.366 
BMI (Kg/m
2
) 27.42± 0.74 27.58± 0.46 27.58± 0.96 26.41 ± 0.27 0.224 
 
Anti H.P, anti-Helicobacter pylori; BMI, body mass index; FBS, fast blood sugar; HDL, high-density lipoprotein; 
LDL-C, low-density lipoprotein; SBP, systolic blood pressure; TG, triglyceride; DBP=diastolic blood pressure. 
Values are means±sd 
 
According to Table 2, 64.96 ± 2.97 and 43.63 ± 
3.07 U/mL of anti-H. pylori IgG  and anti-H. 
pylori IgA, respectively of CAD patient with 
positive H. pylori IgA were significantly higher 
than those found for the CAD patients with 
negative  anti-H. pylori IgA (21.16 ± 11.20 and  
7.40  ±  0.48 U/mL). Controls with the negative 
anti-H. pylori IgA (15.62 ± 5.31 and 6.61± 
0.63U/mL) and the control subjects with  positive  
anti-H. pylori IgA (56.81 ± 4.72 and  38.06 ± 324 
U/mL) respectively. As  shown in Table 3 and 
Figure 1 (A), the serum homocysteine 
concentration of the CAD patients with positive 
anti-H. pylori IgG (27.70 ± 1.28 µmol/L) was 
significantly (P= 0.05) higher than CAD patients 
with negative anti-H. pylori IgG (22.16 ± 2.19 
µmol/L). The difference between the HCY levels 
of CAD patients with positive anti-H. pylori IgG 
(27.70± 1.28µmol/L and the control group with 
positive anti-H.P. IgG (22.38 ± 1.19 µmol /L) was 
significant (P=0.02). The homocysteine levels of 
the CAD patients with positive anti-H. pylori IgG 
(27.70 ± 1.28 µmol/L) was significantly (P=0.02) 
higher than the control subjects with negative anti-
H.P IgG positive (20.62 ± 1.51 µmol /L). The  
serum homocysteine  concentration of the control 
subjects  with  negative anti-H.P IgG positive 
(22.38 ± 1.19 µmol /L)  and control group with 
negative anti-H.P IgG (20.62± 1.51 µmol /L) was  
not different significantly (P= 0.936).  A 
significant correlation  with r= 0.233 , P=0.0.19 
was identified between  anti-H. pylori IgG and  
homocysteine  levels  of  the CAD patients with 
positive anti-H. pylori IgG  (Fig.1 B), while the 
correlation between  the anti-H. pylori IgG and  
homocysteine  levels  of CAD patients with 
negative anti-H. pylori IgG was not significant (r= 
0.005, P=0.493). The correlation  between the anti-
H. pylori IgG and  homocysteine  levels  of  the 
control group with positive and negative anti-H.P 
IgG was not significant (r= -0.071, P=0.325   and   
r= -0.071, P=0.325,  respectively). It is worth to 
note that correlation between the anti-H. pylori 
IgG and homocysteine levels of   all the subjects 
was significant (r= 0.233, P=0.002).  
 
Table 2 - Demographic characteristics of CAD patients and controls with positive and negative H. pylori anti IgA  
 Control- 
Negative anti- 
H.P IgA
 
N-14 
Control-
Positive anti-
H.P IgA 
N=50  
CAD-Negative 
anti-H.P IgA 
N=8 
CAD-Positive 
anti-H.P IgA  
N=88 
P value 
Gender Male 7 25 6 62 0.067 
Female 7 25 2 26 
Smoking Yes 4 9 3 27 0.372 
No 10 41 5 61 
Diabetes History Yes 1 4 2 11 0.490 
H. pylori and Hyperhomocysteinemia 
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No 13 46 6 77 
Medication Aspirin Yes 9 39 6 78 0.089 
No 5 11 2 10 
Statin Yes 5 21 6 66 <0.001 
No 9 29 2 22 
Lozartan Yes 4 8 2 24 0.458 
No 10 42 6 64 
 
Anti H.P IgG( U/mL) 15.62 ± 5.31 56.81 ± 4.72 21.16 ± 11.20 64.96 ± 2.97 <0.001 
Anti H.P IgA( U/mL) 6.81 ± 0.63 38.06 ± 3.24 7.40 ± 0.48 43.63 ± 3.07 <0.001 
LDL-C( mg/dL) 100.25 ± 7.79 97.24 ± 3.98 107.25 ± 9.10 97.67 ± 92.02 0.768 
HDL-C( mg/dL) 39.42 ± 2.40 38.33 ± 1.96 39.75 ± 3.25 36.36 ± 0.85 0.501 
Cholesterol( mg/dL) 178.77 ± 9.79 173.93 ± 7.02 176.88 ± 11.61 168.33 ± 4.00 0.728 
TG( mg/dL) 165.85 ± 28.64 139.76 ± 
14.73 
192.50 ± 35.53 128.71 ± 6.68 0.099 
FBS( mg/dL) 99.07 ± 6.27 104.08± 6.05 112.62 ± 8.99 103.72 ± 2.53 0.817 
 Age(years) 57.79 ± 3.10 55.80 ± 1.50 59.12 ± 2.99 59.18 ± 1.19 0.370 
SBP(mmHg) 128.36 ± 3.06 130.60 ± 2.71 134.43 ± 4.46 131.00 ± 1.78 0.882 
DBP (mmHg) 78.64 ± 2.71 79.73 ± 1.74 81.29 ± 3.10 82.96 ± 1.46 0.418 
BMI(kg/m
2
) 27.99 ± 0.79 27.53 ± 0.44 26.65 ± 1.51 26.61 ± 0.37 0.306 
 
Anti H.P, anti-helicobacter pylori; BMI, body mass index; FBS, fast blood sugar; HDL, high-density lipoprotein; 
LDL-C, low-density lipoprotein; SBP= systolic blood pressure; TG, triglyceride; DBP=diastolic blood pressure. 
Values are means±sd 
 
As shown in Table 4 and Figure 2 A, there was not 
a significant (P=1) difference between the 
homocysteine levels of the CAD patients with 
positive anti-H. pylori IgA (24.70 ± 0.80 µmol/L   
as comparison with the CAD patients with 
negative anti-H. pylori IgA (26.50 ± 4.49 µmol/L).  
Serum  homocysteine concentration of the CAD 
patients with positive anti-H. pylori IgA (24.70 ± 
0.80 µmol/L µmol/L) was not significantly  (P= 
0.1) higher than the control subjects  with  positive 
anti-H. pylori IgA (22.79 ± 1.12 µmol/L) but was 
higher than  the controls with  negative anti-H.P. 
IgA positive (17.85 ± 1.07 µmol/L) significantly 
(P=0.01). The difference between the 
homocysteine levels of the control subjects with 
positive anti-H.P IgA (22.79 ± 1.12 µmol /L) and 
controls with negative anti H. pylori IgA (17.85 ± 
1.07 µmol/L) was not different significantly 
(P=0.34). Serum homocysteine concentration of 
the CAD patients with negative anti-H. pylori IgA 
(26.50 ± 4.49 µmol/L) was not significantly (P= 
0.75) higher than the control subjects with positive 
anti-H. pylori IgA (26.50 ± 4.49 µmol /L). A 
significant correlation (P<0.001, r=0.691) was 
found between the anti- H. pylori IgA and anti H. 
pylori IgG of CAD patients in comparison with 
non-CAD patients (Fig. 3). 
 
 
Figure 1- (A): Homocysteine levels of CAD patients with positive and negative anti H. pylori IgG and controls with 
positive and negative anti H. pylori IgG (B):  The correlation between homocysteine levels and anti H. pylori IgG 
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levels of CAD patients with positive and negative anti H. pylori IgG and of controls with positive and negative anti 
H. pylori IgG groups were identified. 
A)   4 P=0.020 (in comparison with 1); 4 P=0.020 (in comparison with 2); 4, P=0.0 5 (in comparison with 3); 
3, P=1.000 (in comparison with 2); 2, P=0.936 (in comparison with 1); 3, P=0. 935 (in comparison with 1); 
Correlation in   all subjects, r= 0.233, P=0.002; ○) Correlation in controls with negative anti H. pylori IgG, 
r= 0.324, P= 0.076; □) Correlation in controls with positive anti H. pylori IgG, r= -0.071, P=0.325; ♦) 
Correlation in CAD  patients with negative anti H. pylori IgG, r= 0.005, P=0.493; ♦♦) Correlation in CAD 
patients with positive anti H. Pylori IgG, r= 0.233, P=0.0.19. 
 
Table 3 - Homocysteine and anti H. pylori IgG and IgA levels of CAD patients with positive and negative anti-H.P 
IgG 
 
 Control 
(Negative anti-
H.P IgG) 
n=21 
Control 
(Positive 
anti-H.P 
IgG) 
n=43 
CAD 
(Negative 
anti-H.P IgG 
) 
N=17 
CAD 
(Positive anti-
H.P IgG) 
N=79 
P value 
Gender Male 13 19 9 59 0.008 
Female 8 24 8 20 
Smoking Yes 6 7 6 24 0.309 
No 15 36 11 55 
Diabetes History Yes 1 4 4 9 0.306 
No 20 39 13 70 
Medication Aspirin Yes 14 34 15 69 0.129 
No 7 9 2 10 
Statin Yes 8 18 13 59 <0.001 
No 13 25 4 20 
Lozartan Yes 5 7 5 21 0.577 
No 16 36 12 58 
Hemocysteine( µmol/L ) 20.62 ± 1.51 22.38 ± 1.19 22.16 ± 2.19 27.70 ± 1.28 0.003 
Anti H.P IgG ( U/mL ) 8.05 ± 0.40 67.21 ± 4.00 9.34 ± 2.11 72.49 ± 3.64 <0.001 
Anti H.P IgA  ( U/mL) 15.48 ± 3.18 38.90 ± 3.68 12.20 ± 1.15 46.72 ± 3.24 <0.001 
 
Anti H.P, anti Helicobacter pylori; Values are means± sd 
 
Table 4 - Homocysteine and anti H. pylori IgG and IgA levels of CAD patients with positive and negative anti H. 
pylori IgA and the control subjects with positive and negative anti-H. Pylori IgA 
 
 Controls-
Negative anti-
H.P IgA 
N=14 
Controls-
positive anti-
H.P IgA 
N=50 
CADs-
Negative anti-
H.P IgA 
N=8 
CADs- 
Positive anti-
H.P IgA  
N=88 
P value 
Gender Male 7 25 6 62 0.067 
Female 7 25 2 26 
Smoking Yes 4 9 3 27 0.372 
No 10 41 5 61 
Diabetes History Yes 1 4 2 11 0.490 
No 13 46 6 77 
Medication Aspirin Yes 9 39 6 78 0.089 
No 5 11 2 10 
Statin Yes 5 21 6 66 <0.001 
No 9 29 2 22 
Lozartan Yes 4 8 2 24 0.458 
No 10 42 6 64 
 
Hemocysteine (µmol/L) 17.85 ± 1.07 22.79 ± 
1.12 
26.50 ± 4.49 24.70 ± 
0.80 
0.007 
Anti H.P IgG (U/ml) 15.62 ± 5.31 56.81 ± 21.16 ± 11.20 64.96 ± <0.001 
H. pylori and Hyperhomocysteinemia 
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4.72 2.97 
Anti H.P IgA(U/ml) 6.81 ± 0.63 38.06 ± 
3.24 
7.40 ± 0.48 43.63 ± 
3.07 
<0.001 
 
 Values are means±sd 
 
 
 
Figure 2-  (A): Homocysteine levels of the CAD patients with positive and negative anti-H. pylori IgA and controls 
with positive and negative anti-H. pylori IgA. (B):  The correlation between the homocysteine and anti-H. pylori 
IgA levels of CAD patients with positive and negative anti-H. pylori and of the controls with positive and negative 
anti H. pylori IgA groups.   
A) 4 P=0.011(in comparison with 1);  4 P=0.114(in comparison with 2); 4, P=1.000 (in comparison with 3);  3, 
P=0.197(in comparison with 1); 2, P=0.346 (in comparison with 1); 2, P=0.754(in comparison with 3);  B) 
Correlation between all groups, r= 0.197, P=0.006; ○) Correlation for controls with negative anti H. pylori 
IgA, r= 0.324, P= 0.076; □) Correlation for controls with positive anti H. pylori IgA, r= -0.081, P=0.335; ♦) 
Correlation for CAD patients with negative anti H. pylori IgA, r= 0.007, P=0.489; ♦♦) Correlation for CAD 
patients with positive anti H. pylori IgA, r= 0.075, P=0.256. 
 
 
 
Figure 3- Correlation between anti-H. pylori IgG and anti-H. pylori IgA of patients with the controls. r= 0.691, p< 
0.001. 
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DISCUSSION  
 
Several studies have demonstrated that 
hyperhomocysteinemia and H. pylori infection 
have  contributed in the cardiovascular disease 
pathogenesis, independent of other conventional 
risk factors (Sung and Sanderson 1996; Leung et 
al. 2001; Sharma and Aggarwal 2015). As  shown 
in Tables 1 and 2, there was not a significant 
difference between the demographic 
characterization of the patients with CAD and 
controls. According to Figures 1 A and 2 A, a 
significant difference was found between anti-H.P. 
IgG and IgA levels of the patients with CAD (P= 
0.020) and controls (P=0.011). Serum 
homocysteine concentration of the patients with 
CAD was more than the controls significantly. A 
positive correlation was found between the 
homocysteine levels and anti-H. pylori IgG in the 
patients with CAD as comparison to the control 
subjects.  It has been proposed that H. pylori 
infection might modify the serum homocysteine 
concentration in a way that could increase the risk 
of CAD. The results of a case-control study 
showed that H. pylori infection increased a two-
fold risk of CAD (Sung and Sanderson 1996). 
However, the possible mechanism of a chronic 
infection by H. pylori leading to atherosclerosis is 
yet to be identified. One of the proposed 
mechanisms is that H. pylori chronic infection 
increases the acute inflammation factors such as 
fibrinogen and sialic acid, which are predictors of 
CAD (Ringnér et al. 1994). In consistent with 
these results, a higher concentration of fibrinogen 
and total leukocyte count were reported for the 
patients with cardiovascular disease and infected 
by H. pylori as comparison to controls (Patel et al. 
1995). The other hypothesis is that chronic H. 
pylori infection leads to malabsorption of vitamin 
B-6, vitamin B-12 and folate, methylation defeat 
and hyperhomocysteinaemia, thereby inducing 
arterial damage. It has been shown that nitric oxide 
secretion from the endothelial cells is inhibited by 
homocysteine, which comforts platelet aggregation 
and vasoconstriction. The balance between the 
procoagulants and anticoagulants might be 
changed by homocysteine via selective manners 
such as inhibition of the thrombomodulin 
processing and releasing, decreasing the protein C 
activation and inducing a protease activator of 
coagulation factor V (Sung and Sanderson 1996). 
Other mechanisms of H. pylori infection that could 
lead to atherosclerosis are destructive influence of 
H. pylori and its products like cytokines and 
cytotoxins on coronary endothelium, activation of 
immune mechanisms, which react with the nuclei 
of monocytes in atherosclerotic vessel wall and 
cytoplasm of fibroblast-like cell in atherosclerosis 
plaques (Rogha et al. 2012). In agreement with the 
present results, the results of a study on 93 patients 
under diagnostic coronary arteriography with 
infection H. pylori, showed a significant decrease 
of vitamin B12 and folate levels, thereby 
increasing homocysteine levels. They suggested 
that homocysteine could induce endothelial 
damage directly, affect platelet function and 
coagulation factors and increase the oxidation of 
LDL-C, which have critical role in cardiovascular 
disease occurrence (Ringnér et al. 1994). In a 
study patients with H. pylori infection exhibited a 
decreased secretion of ascorbic acid by gastric 
mucosa and elevated gastric pH, thereby the folate 
absorption from the diet was decreased due to low 
ascorbic acid in gastric juice, and subsequently a 
significant rise was found in homocysteine levels 
(Lucock et al. 1995). However, it is important to 
consider that confounding variables such as 
vitamin deficiency, acute-phase response to 
vascular diseases, medication use, hypertension, 
advanced age and gender are well-known factors 
influencing homocysteinemia and should be 
considered. An inverse relationship was 
demonstrated among the homocysteine levels and 
H. pylori infection in the patients with functional 
dyspepsia in a cross-sectional study by Rasool et 
al. (2012). The authors showed that 46.2% of H. 
pylori- positive patients had 
hyperhomocysteinemia (>15 μmol/L) when 
compared to H. pylori- negative group (44%). 
They also reported that this was a higher 
proportion in comparison with that was observed 
in healthy population (Rasool et al. 2012). The 
results demonstrated that H. pylori did affect 
directly HCY metabolism in the liver (Cenerelli et 
al. 2002; Longo-Mbenza et al. 2012).  They 
showed that disrupted metabolism of HCY, which 
was  induced by H. pylori led to an increase of 
HCY levels similar to those found in diabetic 
patients. Emphasizing the probable impairment of 
insulin function regarding the regulation of HCY 
level through the  homocysteine/methionine 
metabolism, which  caused  higher levels of HCY 
in the CAD patients infected by H. pylori and the 
importance of H. pylori  infection  in determining  
the elevated HCY levels.  
H. pylori and Hyperhomocysteinemia 
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In summary, a small sample size was investigated 
and these observations should be confirmed in a 
larger sample of the patients with more analysis 
works. Here, only two independent variables were 
analysed, but it would be worthwhile to consider 
other probable variables involving in CAD disease 
in future studies. 
 
CONCLUSION 
 
The present study demonstrated an inverse 
relationship between the homocysteine levels and 
H. pylori seropositivity (IgG and IgA) and 
atherosclerosis occurrence in the patients with 
CAD. Since classic risk factors were not able to 
explain all cases of CAD, the results of present 
study suggested that chronic H. pylori infection 
affected the development or maintenance of CAD, 
since it induced chronic long term infection within 
gastric epithelium, which led to not only local but 
systemic inflammation. According to the present 
findings, the involvement of H. pylori in this 
process was based on the chronic inflammation, 
which might facilitate the CAD-related 
pathologies. Moreover, impact of the presence of 
H. pylori was found on homocysteine levels in 
such patients. 
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